Latest A3P Biomedical News & Updates

See the latest news and media coverage for A3P. We track all announcements, press releases, and industry mentions in real time, all in one place.

A3P Biomedical (A3P)

Developer of blood-based prostate cancer diagnostic tests

a3p.com

Headquarters: Stockholm, Sweden
Founded year: 2018
Company type: Private company
Number of employees: 40–50

Last updated Today

Latest news about A3P Biomedical (A3P)

In short: A3P advanced its Stockholm3 prostate cancer test through major clinical validations, global market launches, and key leadership transitions.

Company announcements

Today A3P

A3P announces study showing Stockholm3 detects aggressive prostate cancers

The study in Annals of Internal Medicine found 90% sensitivity for aggressive prostate cancer, outperforming PSA.

March 24 A3P

A3P elects O’Connell Chairman and Steinberg CEO

O’Connell brings decades of life sciences experience. Steinberg, co-founder, leads operations and strategy. Transition focuses on global expansion.

March 19 A3P

A3P Biomedical highlights Stockholm3 study as Editor’s Choice

The landmark STHLM3 study in European Urology shows Stockholm3 detects aggressive prostate cancers missed by PSA. CEO Martin Steinberg welcomes the recognition.

March 16 A3P

A3P announces Stockholm3 study wins Best Oncology Abstract at EAU26

The independent study shows Stockholm3 reduces MRI and biopsy needs in Sweden's prostate cancer screening while detecting significant cases.

Media coverage

Yesterday Markets Insider

Pioneering screening test offers potential to find more aggressive prostate cancers

This large-scale, high-quality trial compares a promising alternative screening test to PSA. This may be the breakthrough for prostate cancer screening that we have all...

4 November 2025 Placera.se

A3P Biomedical: Stockholm3 screening detects aggressive and potentially deadly prostate cancer that is missed by PSA at current threshold values

A3P Biomedical: Stockholm3 screening detects aggressive and potentially deadly prostate cancer that is missed by PSA at current threshold values.

5 March 2025 Affärsvärlden

The pharmaceutical veteran Thomas Eldered is a major shareholder and chairman of the investment company Flerie. Photo: Tobias Ohls. This is evident from a press release. A3P Biomedical has developed Stockholm3, a blood-based..

The pharmaceutical veteran Thomas Eldered is a major shareholder and chairman of the investment company Flerie. Photo: Tobias Ohls. This is evident from a press release. A3P Biomedical has developed Stockholm3, a blood-based...

13 August 2021 PR Newswire

A3P Biomedical AB: Fast track publication of the STHLM3 MRI trial in The Lancet Oncology

STOCKHOLM, Aug. 13, 2021 /PRNewswire/ -- A3P Biomedical AB today announced that the publication of the STHLM3 MRI trial including 12,750 men has been fast...

Never miss news about A3P

Track A3P and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

A3P competitors & trending companies

Browse news for competitors to A3P and other trending companies.